1. Home
  2. NVCR vs SUPN Comparison

NVCR vs SUPN Comparison

Compare NVCR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NovoCure Limited

NVCR

NovoCure Limited

HOLD

Current Price

$13.35

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$47.22

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVCR
SUPN
Founded
2000
2005
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
2.6B
IPO Year
2015
2012

Fundamental Metrics

Financial Performance
Metric
NVCR
SUPN
Price
$13.35
$47.22
Analyst Decision
Buy
Strong Buy
Analyst Count
6
4
Target Price
$28.42
$63.25
AVG Volume (30 Days)
1.7M
639.4K
Earning Date
10-30-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$642,269,000.00
$681,539,000.00
Revenue This Year
$9.75
$8.32
Revenue Next Year
$5.62
$23.36
P/E Ratio
N/A
N/A
Revenue Growth
11.17
4.54
52 Week Low
$10.70
$29.16
52 Week High
$34.13
$57.65

Technical Indicators

Market Signals
Indicator
NVCR
SUPN
Relative Strength Index (RSI) 60.37 53.47
Support Level $10.79 $45.36
Resistance Level $13.94 $47.26
Average True Range (ATR) 0.61 1.23
MACD 0.22 0.36
Stochastic Oscillator 80.48 92.10

Price Performance

Historical Comparison
NVCR
SUPN

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: